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Abstract
The human UBE3A gene, which is essential for normal neurodevelopment, encodes three Ubiquitin E3 ligase A (UBE3A)
protein isoforms. However, the subcellular localization and relative abundance of these human UBE3A isoforms are
unknown. We found, as previously reported in mice, that UBE3A is predominantly nuclear in human neurons. However, this
conserved subcellular distribution is achieved by strikingly distinct cis-acting mechanisms. A single amino-acid deletion in
the N-terminus of human hUBE3A-Iso3, which is homologous to cytosolic mouse mUBE3A-Iso2, results in its translocation
to the nucleus. This singe amino-acid deletion is shared with apes and Old World monkeys and was preceded by the
appearance of the cytosolic hUBE3A-Iso2 isoform. This hUBE3A-Iso2 isoform arose after the lineage of New World monkeys
and Old World monkeys separated from the Tarsiers (Tarsiidae). Due to the loss of a single nucleotide in a non-coding exon,
this exon became in frame with the remainder of the UBE3A protein. RNA-seq analysis of human brain samples showed that
the human UBE3A isoforms arise by alternative splicing. Consistent with the predominant nuclear enrichment of UBE3A in
human neurons, the two nuclear-localized isoforms, hUBE3A-Iso1 and -Iso3, are the most abundantly expressed isoforms of
UBE3A, while hUBE3A-Iso2 maintains a small pool of cytosolic UBE3A. Our findings provide new insight into UBE3A
localization and evolution and may have important implications for gene therapy approaches in Angelman syndrome.
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Introduction
Ubiquitin E3 ligase (UBE3A) is a HECT (Homologous to E6AP
C-Terminus) E3 ligase, required for normal neurodevelopment
(1). Although expressed biallelically in most tissues, UBE3A is
expressed exclusively from the maternal allele in neurons (2)
and changes in neuronal UBE3A activity has major impact on
neurodevelopment (3). Loss of functional UBE3A in the brain
leads to Angelman syndrome (AS) (1,4,5). Conversely, increased
levels of UBE3A appear to function critically in the pathophys-
iology of Dup15q syndrome and have been associated with
autism spectrum disorder (ASD) (6,7). Yet, despite the extensive
evidence implicating UBE3A in severe neurodevelopmental dis-
orders, relatively little is known about the distinct isoforms of
UBE3A.
Several studies have shown that UBE3A is highly enriched
in the nucleus of mouse and human neurons (8,9), but pro-
tein labeling has also been observed in the cytosol, in particu-
lar within dendritic spines and axon terminals (10,11). Recent
work has revealed a mechanism guiding the subcellular local-
ization of UBE3A (9,12). Mice express two distinct UBE3A protein
isoforms, which differ in their N-terminus. The shorter, more
abundantly expressed, mouse isoform 3 (mUBE3A-Iso3) is pre-
dominantly localized to the nucleus, whereas the longer, less
abundant, mUBE3A-Iso2 isoform, which possesses a N-terminal
extension of 21 amino acids, is mainly localized in the cytosol
(9). Importantly, only the selective loss of the nuclear-localized
mUBE3A-Iso3 in mice results in behavioral and electrophysi-
ological deficits resembling AS (9,13). In humans, differential
splicing generates three protein isoforms (14), two of which,
hUBE3A-iso1 and hUBE3A-iso3, are highly homologous to the
mouse isoforms 3 and 2, respectively (Fig. 1A). In addition, a third
human UBE3A isoform has been reported (hUBE3A-Iso2), which
has no homologue in mice (14). Similar to mice, loss of the most
abundantly expressed short isoform (hUBE3A-Iso1) in human
results in a AS-like phenotype (15), but the localization of this
human isoform has not been established.
Although the human UBE3A isoforms were described over
two decades ago (14), still very little is known about how these
isoforms are generated, their relative abundance and their sub-
cellular localization. Here we report that, although the overall
subcellular distribution of UBE3A in human-derived neurons
resembles that of mouse primary neurons, the localization of
human UBE3A is accomplished through a distinct mechanism.
The human homologues of the two mouse UBE3A isoforms are
both localized in the nucleus, whereas the hUBE3A-Iso2, which
is shared with Old- and New World monkeys, is localized in the
cytosol.
Results
Human UBE3A-iso1 and -iso3 are enriched in the
nucleus while hUBE3A-Iso2 is cytosolic
We have previously shown that human UBE3A is highly
enriched in the nucleus, as observed in cultured human
iPSC-derived neurons and in postmortem human brains (9)
(Supplementary Material, Figure S1A). To investigate how this
overall subcellular distribution of UBE3A is achieved, we
determined the subcellular localization of each of the three
human UBE3A isoforms. We generated constructs that express
each individual (untagged) isoform under the control of the CMV
early enhancer/chicken β-actin/β-globin (CAG) promoter, and a
tdTomato fluorescence reporter under the control of the PGK
promoter to identify transfected neurons (16) (Supplementary
Material, Figure S1B). In the constructs of the long isoforms
(hUBE3A-Iso2 and -Iso3), the second ATG codon was mutated to
ensure the expression of only the long isoforms from each of
these constructs (Supplementary Material, Figure S1B).
These constructs were transfected to human iPSC-derived
AS neurons and localization in mature neurons was assessed
by immunocytochemistry (Fig. 1C). Analogous to the nuclear
localization of the short mUBE3A-Iso3 in mouse (9) (Fig. 1B),
the hUBE3A-Iso1 orthologue was predominantly located in the
nucleus (Fig. 1C). Remarkably, hUBE3A-Iso3, which is highly
homologous to the cytosolic mUBE3A-Iso2, also localized
predominantly to the nucleus (Fig. 1C). In contrast, the unique
hUBE3A-Iso2 showed a clear cytosolic localization (Fig. 1C).
Overexpression of the human UBE3A isoforms in primary
murine AS hippocampal neurons (Fig. 1D) yielded the same
localization as in AS iPSC-derived neurons and in non-neuronal
human Bone Osteosarcoma Epithelial (U2OS) cells (Fig. 1C;
Supplementary Material, Figure S1C). This indicates that the
isoform-specific neuronal subcellular localization of UBE3A is an
intrinsic property of the protein and not affected by possible dif-
ferences in trans-acting factors between two species (i.e. human
versus mouse), and independent of cell type (i.e. neuronal versus
non-neuronal) (Fig. 1 and Supplementary Material, Figure S1C).
Thus, in both humans and mice, the overall distribution
of UBE3A appears to be determined exclusively by the dis-
tinct isoforms, each of which has a defined subcellular
localization.
The N-terminal extension of UBE3A dictates subcellular
localization
The above experiments indicate that the N-terminal amino acid
sequence of UBE3A is critical for determining its subcellular
localization. To test whether the addition of a short N-terminal
tag affects the subcellular distribution of the nuclear-localized
isoforms (mUBE3A-Iso3 and hUBE3A-Iso1), we N-terminally
tagged both isoforms with the HA (hemagglutinin) tag and
overexpressed them in AS mouse primary neurons. Strikingly,
addition of an N-terminal HA-tag to the (short) nuclear mUBE3A-
Iso3 or hUBE3A-Iso1 homologues resulted in their relocation to
the cytosol. However, adding the tag to the nuclear hUBE3A-Iso3
or to the cytosolic hUBE3A-Iso2 did not affect the localization of
either of these proteins (Fig. 1E).
It is remarkable that although mUBE3A-Iso2 and hUBE3A-
Iso3 share an almost identical N-terminal amino acid extension
that differs at only three positions, their localization is strikingly
different (mUBE3A-Iso2, cytoplasmic; hUBE3A-Iso3, nuclear;
Fig. 1). To address whether the distinct localization of these
two homologs is solely dictated by their N-terminal extensions
(and not by other differences in the UBE3A protein), we
swapped the N-terminal extensions of mUBE3A-Iso2 and
hUBE3A-Iso3, thereby creating chimeric mext2hUBE3A-Iso3
and hext3mUBE3A-Iso2 proteins (Fig. 2A). The localization of
these chimeric proteins was determined in both primary
murine AS hippocampal neurons (Fig. 2B) and hiPSC-derived
AS neurons (Fig. 2C). In both human and mouse neurons, the
localization of the two isoforms was inverse, with hext3mUBE3A-
Iso2 showing a nuclear localization and mext2hUBE3A-Iso3
a cytosolic localization. Collectively these results indicate
that the differential localization of these UBE3A isoforms
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Figure 1. Localization of mouse and human UBE3A isoforms. (A) Schematic overview (top) of the domains of UBE3A and the N-terminal sequences (bottom) of the
different mouse (blue) and human (orange) UBE3A isoforms. (B) Localization of mUBE3A isoforms in hippocampal neurons derived from E16.5 Ube3am−/p+ (AS) embryos.
Neurons transfected at DIV7 with untagged mUBE3A-Iso2 or mUBE3A-Iso3 were fixed and stained at DIV10. Neurons were stained for UBE3A (green, left panels) together
with MAP2 (pink) and DAPI (blue) (right panels). (C) Localization of hUBE3A isoforms in hIPSC-derived AS neurons. Neurons transfected after 6 weeks of differentiation
with untagged hUBE3A-Iso1, hUBE3A-Iso2 or hUBE3A-Iso3 were fixed and stained 2 days after transfection. Staining was as described for (B). (D) Localization of hUBE3A
isoforms in mouse hippocampal AS neurons. Neurons transfected at DIV7 with hUBE3A-Iso1, hUBE3A-Iso2 and hUBE3A-Iso3 were fixed and stained as described for
(B). (E) Localization of HA-tagged mUBE3A-Iso3 and human UBE3A isoforms in mouse hippocampal AS neurons. Neurons were fixed and stained as described for (B).
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Figure 2. The N-terminal extension of UBE3A dictates its localization. (A) Schematic overview of the chimeric UBE3A constructs in which the N-terminal extensions
of mUBE3A-Iso2 and hUBE3a-Iso3 were swapped. (B and C) Localization of chimeric hext3mUBE3A-Iso2 and mext2hUBE3A-Iso3 constructs after transfection in mouse
hippocampal AS neurons (B) or into hIPSC-derived AS neurons (C). (D) Schematic overview of the ancestral ‘MATACK’ N-terminal extension (see Fig. 3) and the sequences
found in Homo sapiens and Cercopithecidae (Old World Monkeys), Cetartiodactyla (wild boar and whale) and Mus musculus (mouse). (E) Localization of chimeric UBE3A
constructs in mouse hippocampal AS neurons. Neurons were transfected at DIV7 with hUBE3A-Iso3 harboring the ancestral ‘MATACK’ extension or the extension of
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Figure 3. Molecular evolution of UBE3A isoforms. Molecular evolution of the (N-terminal extension of) UBE3A isoforms in placental mammals. Stars indicate changes
to the ancestral N-terminal sequence, MATACKRSPGEPQSDD, and are indicated in magenta. The three amino acid positions different between the mUBE3A-Iso2 and
hUBE3A-Iso3 are underlined in black. The orange hexagon marks the time in evolution when hUBE3A-Iso2 first is predicted to start being expressed.
A unique deletion of a Proline in the N-terminal
extension of hUBE3A-Iso3 results in its translocation to
the nucleus
The N-terminal ‘MATACK’ leader sequences of mUBE3A-Iso2
and hUBE3A-Iso3, differ only at three positions: Proline (P) 9
in the mUBE3A-Iso2 is missing in hUBE3A-Iso3, Serine (S) 12
in mUBE3A-Iso2 is a Proline in hUBE3A-Iso3 and Glutamate
(E) 15 in mUBE3A-Iso2 is an Aspartate (D) in hUBE3A-Iso3
(Figs 1A and 2D). To decipher which of these changes might be
responsible for determining the differential subcellular location,
we first investigated their molecular evolution. A basic local
alignment search tool (BLAST) analysis on protein sequences
was performed, using residues 1–16 of hUBE3A-Iso3 as a query
sequence. A multiple sequence alignment of the identified
sequences indicated an ancestral sequence of the placental
mammals (Placentalia) that possesses a Proline at positions 9
and 12 and an Aspartate at position 15, which is shared amongst
most branches of the mammalian evolutionary tree (Fig. 3,
Supplementary Material, Figure S2A). Notably, we also found
that the majority of evolutionary changes that subsequently
occurred in the ‘MATACK’ leader sequence are confined to these
three residues (amino acids 9, 12 and 15).
The conservative change of D15E in mouse mUBE3A-Iso2
was also observed in other rodents (rats, gerbils) of the Muri-
dae family, suggesting that this substitution occurred late in
rodent evolution. The P12 to mouse S12 substitution occurred
even later in rodent evolution, but it was additionally observed
in other minor branches of mammals (e.g. Camelidae) (Fig. 3).
The Proline at position 9 has been substituted for a Serine at
several instances during evolution but is most notably frequent
in the branch of all Cetartiodactyla, which includes all even-toed
ungulates (hoofed animals), whales and dolphins. However, the
deletion of this amino-acid in human hUBE3A-Iso3 is highly
unique and shared only with Great Apes and Old World Monkeys
(collectively referred to as Catarrhini), but not New World Mon-
keys. These findings suggest that the Proline 9 deletion arose
during recent primate evolution, around the time of divergence
of Catarrhini and New World monkeys, less than 25–40 million
years ago (Mya) (Fig. 3).
To identify the critical substitutions responsible for the dif-
ferential subcellular localization of mUBE3A-Iso2 and hUBE3A-
Iso3, we constructed chimeric proteins in which the ‘MATACK’
leader sequence of hUBE3A-Iso3 was replaced by the ances-
tral ‘MATACK’ sequence along with the substitutions found in
Cetartiodactyla (Fig. 2D). Since the localization of overexpressed
UBE3A isoforms is not dependent on the host cell species (Fig. 1),
the localization of these chimeric isoforms was investigated in
primary mouse AS neurons. Chimeric isoforms harboring the
ancestral ‘MATACK’ leader sequence or the ‘MATACK’ sequence
as found in Cetartiodactyla showed a predominantly cytosolic
localization (Fig. 2E), mirroring the subcellular distribution of
mouse mUBE3A-Iso2. Hence, the deletion of Proline 9 (mUBE3A-
Iso2 numbering) in the ‘MATACK’ leader sequence is responsible
for the nuclear localization of hUBE3A-Iso3, an isoform that is
selectively present among Catarrhini.
Appearance of the cytosolic hUBE3A-Iso2 during
primate evolution preceded relocation of hUBE3A-iso3
to the nucleus
The above experiments establish that humans possess two
UBE3A isoforms (hIso1 and hIso3) that are both predominantly
nuclear and one cytosolic isoform (hUBE3A-Iso2). Given the
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and human, we hypothesized that the highly unusual deletion
of the Proline in the Catarrhini ‘MATACK’ leader sequence which
relocates UBE3A to the nucleus, was only tolerated in evolution
after the cytosolic hUBE3A-Iso2 had arisen and took over the role
of UBE3A in the cytosol. To address this intriguing evolutionary
question, we investigated the genomes of selected species
for the presence of the exon that encodes the ‘MEKL’ leader
sequence (Supplementary Material, Figure S2B). We found that
indeed different variations of the ‘MEKL’ exon can be traced back
to all mammalian clades (both in placental and non-placental
mammals). However, it is a non-coding exon in most species
since it possesses a nucleotide insertion 3′ of the start codon
(ATG) that results in an out-of-frame exon. We also identified
several species in which the exon had acquired mutations that
disrupt the open reading frame by altering the start codon (ATG),
or in which it had lost critical splicing sites (or a combination
of these changes). Thus, there has been little (to none)
selective pressure on this non-coding exon, and consequently,
many additional mutations in this sequence can be observed
in various species (Supplementary Material, Figure S2B and
Supplementary Material, Table S1). Only after the lineage of New
World monkeys and Old World monkeys separated from the
Tarsiers (Tarsiidae) (40–58 Mya), a single nucleotide in this non-
coding exon was lost, which then allowed the translation of the
in-frame ‘MEKL’ encoding exon. Hence, the cytosolic hUBE3A-
Iso2 ‘MEKL’ isoform arose before the deletion of the Proline in
the human ‘MATACK’ leader sequence occurred, which relocates
the hUBE3A-Iso3 isoform to the nucleus.
Human UBE3A isoforms are generated by alternative
splicing, while mice isoforms arise via alternative
translation
In a previous study, we demonstrated that the nuclear short
mUBE3A-Iso3, as well as its nuclear homologue hUBE3A-Iso1,
are the most abundantly expressed protein isoforms in mouse
and human brain, respectively, constituting approximately
80% of all UBE3A protein (9). Since hUBE3A-Iso2 and hUBE3A-
Iso3 isoforms cannot be separated on a western blot, their
combined contribution was estimated to be 10–20% of total
UBE3A protein. To gain more insight into the relative expression
level of each human UBE3A isoform, we analyzed a previously
published human cortex RNA-seq dataset (17) (human cortex
autopsy tissue from individuals with no history of neurological
disorders; cause of death was an acute cardiorespiratory
failure) and determined the abundance of each distinct
UBE3A transcript based on an analysis of alternatively spliced
exons. We used the Integrated Genome Viewer (IGV) software
to generate Sashimi plots for every sample of the dataset
(Supplementary Material, Figure S3A) and quantified the exon
junctions occurring in the UBE3A transcripts (Fig. 4A and B).
Similar to what has been observed previously by sequencing of
human UBE3A transcripts (14), we found two UTRs preceding the
coding UBE3A sequence. In addition, we observed a non-coding
exon between coding exons 4 and 6 that has been reported
previously (14) and is now also annotated in the latest version of
the human reference genome. Its presence was observed in the
majority of the transcripts and its inclusion prevents translation
of UBE3A from the upstream exons (exons 3 and 4) that encode
the ‘MATACK’ and ‘MEKL’ N-terminal extensions. Hence, even
though these ‘MATACK’ and ‘MEKL’ coding exons are present in
a large number of transcripts, the presence of the non-coding
exon results in the synthesis of the short (nuclear) hUBE3A-Iso1,
which initiates translation at the methionine of the MKRAAAK
sequence encoded by exon 6/7 (Fig. 4C). Based on the frequency
of exon junctions as indicated in the Sashimi plots (Fig. 4B), we
identified all possible splice variants that potentially encode any
of the three isoforms and calculated their relative abundance (as
% of total UBE3A transcripts in the data set) (Fig. 4C). According
to these calculations the majority of transcripts encodes for
the short nuclear isoform, hUBE3A-Iso1 (82%), which is entirely
consistent with our protein data (9). Transcripts potentially
encoding nuclear hUBE3A-Iso3 are characterized by the presence
of the ‘MATACK’ exon, but with the obligatory absence of the
‘MEKL’ and non-coding exon (incorporation of either exon
would result in premature termination of translation), which
accounts for 17% of the total transcripts. Lastly, transcripts
that could potentially encode the cytosolic hUBE3A-Iso2 are
characterized by the presence of the ‘MEKL’ exon and absence of
the non-coding exon. We only observed 1% of such transcripts,
which also consistently included the ‘MATACK’ exon. Given
that the translation initiation codon of the ‘MEKL’ exon has a
more favorable Kozak sequence (18) compared to the ‘MATACK’
exon, and that its presence renders the ‘MATACK’ exon out-of-
frame, it is likely that translation of this transcript starts at the
‘MEKL’ exon to generate the hUBE3A-Iso2 protein (Fig. 4C and
Supplementary Material, Figure S3D). Using the same methodol-
ogy, we quantified the expression levels of each UBE3A isoform
in an in vitro model, an already published RNA-seq dataset of
forebrain-patterned neural progenitor cells (NPCs) derived from
human embryonic stem cells (hESC), at week 6 of differentiation
(19). The ratio of UBE3A isoforms in these cells is similar to the
brain samples, with transcripts that would encode hUBE3A-Iso1
making up the majority of total UBE3A (80.6%), hUBE3A-Iso3
being the second most abundant UBE3A isoform (17%), and
the remaining 2.4% of transcripts encoding for the cytosolic
hUBE3A-Iso2 (Supplementary Material, Figure S3B and C).
Previous studies have suggested that the expression of
distinct mouse UBE3A isoforms is controlled by alternative
splicing as well (12,20,21). However, those findings relied
exclusively on RT-PCR analyses, which may fail to capture
changes in relative abundance due to the use of different primer
sets. Hence, we quantified the RNA-seq data to investigate the
relative abundance of the mouse UBE3A isoforms. Surprisingly,
we observed that the majority of transcripts (62%) contained
the ‘MATACK’ exon of the longer cytosolic mUBE3A-Iso2
(Fig. 4D and E). In contrast, only 38% of the transcripts was
specific for the short (nuclear) mUBE3A-Iso3. Given that at
the protein level 75–80% of the total UBE3A protein present in
mouse brain is the short isoform (9), it must be concluded that
regulation of the mouse protein isoforms is heavily regulated by
alternative translation, in which transcripts that contain both
the ‘MATACK’ and ‘MKRAAAK’ exons favor the translation of the
short (nuclear) mUBE3A-Iso3.
Discussion
In the present study, we have determined the subcellular local-
ization of the three human UBE3A isoforms using both human
iPSC-derived neurons and mouse primary neurons. We showed
that, similar to mouse (9), the shortest and most abundantly
expressed isoform (hUBE3A-Iso1) is predominantly nuclear. This
is in line with previous studies that showed that human UBE3A
immunoreactivity is highly enriched in the nucleus of human
brain and human iPSC-derived neurons (9,11).
A rather surprising finding from our study is that hUBE3A-
Iso3, which is highly homologous to the cytosolic localized
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Figure 4. 5′ coding region of the UBE3A gene and predicted splicing pattern of transcripts. (A) Schematic representation of the first seven exons of UBE3A. UTR stands
for untranslated region, NC for non-coding. Exon numbering according to LaSalle et al. (2). (B) Schematic representation of the number of UBE3A exon junctions found
in the human cortex RNA-seq dataset. (C) Splicing pattern of predicted UBE3A transcripts. Splicing pattern and relative abundance of each isoform producing transcript
are based on the quantification of exon junctions in the human cortex RNA-seq dataset shown in (B). Putative initiation ATGs (arrows) and stop codons (asterisks)
upstream of the initiation ATG are indicated for each predicted transcript. The predicted transcripts producing hUBE3A-Iso3 and hUBE3A-Iso2 contain a downstream
initiation codon (dashed arrows) that could potentially also result in the synthesis of hUBE3A-Iso1. (D) Schematic representation of the number of Ube3a exon junctions
found in the mouse RNA-seq dataset. (E) Splicing pattern of predicted Ube3a transcripts. Splicing pattern and relative abundance of each isoform producing transcript
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By swapping the N-terminal extensions of the mouse isoform 2
and human isoform 3, we show that the N-terminal extension
dictates UBE3A isoform localization, irrespective of the cell-type
or species origin in which the UBE3A isoform is expressed. This
observation allowed us to use the mUBE3A-Iso2/hUBE3A-Iso3-
like extensions of a variety of species to identify the crucial
change in the hUBE3A-Iso3 extension that caused the protein
to switch from the cytosol to the nucleus: loss of the Proline
residue at position 9. Evolutionary analysis of the mUBE3A-
Iso2/hUBE3A-Iso3-like extensions revealed that the variant
lacking the proline at position 9 is only present in human, Apes
and Old World monkeys (Catarrhini), and must therefore have
arisen 25–40 Mya. Although the exact mechanism by which the
N-terminal extension mediates differential localization remains
to be established, our previous work in mice suggested that the
cytosolic mUBE3A-Iso2, following initial targeting to the nucleus
through interaction of the UBE3A AZUL domain with PSMD4
(9,22), is actively transported out of the nucleus. Since there
is no nuclear export signal in either of the UBE3A extensions,
our results suggest that loss of Proline 9 interferes with nuclear
export by affecting protein folding and/or interaction with other
proteins, ultimately resulting in nuclear retention of UBE3A. The
importance of the N-terminal extension for UBE3A localization is
supported by the observation that the addition of an N-terminal
HA-tag to the mouse or human short nuclear isoform results
in a dramatic shift of UBE3A into the cytosol. This observation
provides a warning regarding the interpretation of functional
studies that use N-terminal tagged UBE3A, since a change in
UBE3A localization is also likely to change its function. Further
investigations are required to unravel the precise mechanism
by which the N-terminal extension regulates the subcellular
localization and function of UBE3A.
While a transcript encoding hUBE3A-Iso2 was reported more
than two decades ago (14), its abundance has only now been
quantified, based on the analysis of human cortical RNA-seq
data. While the majority of UBE3A transcripts encode hUBE3A-
Iso1 (82%) and hUBE3A-Iso3 (17%), we find that approximately
1% of the UBE3A transcripts encode hUBE3A-Iso2. These
transcript levels correspond well with the reported protein
levels of hUBE3A-Iso1 (∼80%), and the combined protein levels
of hUBE3A-Iso2 and UBE3A-Iso3 (∼20%) in human brain (9).
These findings imply that the novel hUBE3A-Iso2 isoform has a
low abundance in human brain. This is of particular relevance
because this isoform has been frequently used in studies of
UBE3A function, most likely since it encodes the longest UBE3A
protein isoform [e.g. (23–25)].
Our evolutionary analysis of the UBE3A isoforms indicates
that the nuclear localization of hUBE3A-Iso3 followed the emer-
gence of the evolutionarily novel cytosolic isoform, hUBE3A-Iso2.
At the DNA level, this exon can be found in all investigated
mammals, but it only became an in-frame, protein-coding, exon
approximately 40–60 My ago, when a single nucleotide was
lost after New World monkeys and Catarrhini separated from
Tarsiers. The finding that the emergence of the novel cytosolic
isoform preceded the mutation that caused hUBE3A-Iso3 to
move to the nucleus is suggestive of an evolutionary pressure
to maintain at least a small cytosolic pool of UBE3A, and points
toward an important role for UBE3A in the cytosol. Whether this
cytosolic UBE3A activity is required for neuronal function, as
well as for the pathophysiology of AS, remains to be established.
A study in which specifically the cytosolic mUBE3A-Iso2 was
deleted in mice, showed no behavioral phenotypes and changes
in synaptic function, and the behavioral deficits of AS mice
could be fully recapitulated by selective deletion of the nuclear
mUBE3A-Iso3 isoform (9). Recently three individuals with AS
have been described who specifically lack the nuclear hUBE3A-
Iso1 (15). Based on the isoform localization, we determined in
this study, we would predict that this mutation causes a loss
of most of the nuclear UBE3A and that the cytosolic UBE3A
levels remain the same. These AS patients showed the typical
facial features of AS and severe neurodevelopmental delay, as
well as different combinations of the behavioral features, such
as happy disposition, easily provoked laughter, hand-flapping,
hyperkinesia, short attention span, easy excitability, sleep issues
and seizures. In terms of speech and motor skills, the individuals
performed at a developmental level of 2–6 years, which is appre-
ciably better than a typical AS patient with a 15q11–13 deletion
and somewhat better than the higher functioning patients with
a UBE3A mutation. It is likely that this milder profile is caused
by the presence of residual (nuclear) hUBE3A-Iso3 and (cytosolic)
hUBE3A-Iso2 proteins.
In an elegant study published alongside our own, Cham-
berlain and co-workers successively deleted each of the three
UBE3A isoforms from human iPS-derived neurons, in turn
enabling the focused study of the remaining UBE3A proteins
(26). Despite our different experimental approaches (i.e. deletion
of endogenous isoforms versus exogenous overexpression of
isoforms), our studies produced several convergent findings:
first, Chamberlain and co-workers showed that hUBE3A-Iso1
is the predominant protein (84–88%), which matches very well
with our calculation of 82%, based on mRNA quantification.
Second, in agreement with our work and previous studies (8–
11), the authors further found that UBE3A immunoreactivity
is highly enriched in the nucleus of human neurons, and to a
much lower extent, in neuronal processes. Finally, they show
that nuclear UBE3A enrichment in undifferentiated hESC cells
is lower compared to differentiated neurons, similar to what we
previously found for immature mouse neurons (9). But notably,
despite predominant UBE3A immunoreactivity in the nucleus of
differentiated neurons, they found only 30% of UBE3A protein in
the nuclear/mitochondrial pellet upon subcellular fractionation.
Given our finding that the ‘cytosolic’ hUBE3A-Iso2 isoform
constitutes only approximately 1% of the UBE3A transcripts,
the biochemical and immunohistochemistry data appear to
be discrepant, but maybe reconciled by a number of plausible
explanations. First, possibly, the low mRNA transcript level of the
cytosolic hUBE3A-Iso2 may not faithfully reflect the abundance
of the protein; however, this does not appear to be the case,
as the amount of hUBE3A-Iso2 protein in Chamberlain study
correlates very well with the amount of hUBE3A-Iso2 mRNA as
determined in our study. Second, as suggested by Chamberlain
and co-workers, it could be that the volume of the neuropil is
so much larger than the nucleus, that a cytosolic signal can be
hardly observed by immunohistochemistry. Considering that the
nucleus represents 10% of the total neuronal volume, and 30%
of total UBE3A resides in the nucleus, it follows that the nuclear
enrichment as assessed by immunohistochemistry would
approximately be 3-fold. However, immunohistochemistry data
from mature neurons—in our study and in all previously
studies to date—indicates a much greater concentration of
nuclear UBE3A (8–11). Moreover, following transfection with
UBE3A isoform constructs, strong nuclear UBE3A enrichment
manifested even in U2OS cells in which the cytoplasm to nucleus
ratio is closer to 1:1 (Supplementary Material, Figure S1C). Third,
overexpression of the hUBE3A-Iso1 and Iso3 (nuclear) isoforms
could conceivably exaggerate their nuclear localization, but this
seems unlikely as UBE3A is dependent on binding PSMD4 to
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biochemical fractionation may underestimate levels of UBE3A
in the nucleus relative to other compartments. This notion is
also supported by the finding of Chamberlain and co-workers of
similarly low amounts of UBE3A protein in the nuclear fractions
of (undifferentiated) ESCs and neurons, despite comparable
cytosolic and nuclear volumes of the former. Hence, one would
expect (at least) equivalent UBE3A protein levels in the nuclear
fraction compared to the cytosolic fraction of ESCs. Thus, further
studies are needed to address how much UBE3A is truly in the
nucleus, and to address its role in this subcellular compartment.
Considering the very good match of the transcriptome data
(this study) and proteome data (9,26), the expression of dis-
tinct human UBE3A isoforms appears to be entirely governed
by alternative splicing. But unlike human UBE3A isoforms, our
data suggest that mouse UBE3A protein isoforms arise to a large
extent by alternative translation. Although the short (nuclear)
mUBE3A-Iso3 constitutes almost 80% of the protein (9), the
transcripts that uniquely encode mUBE3A-Iso3 represent less
than 40% of total Ube3a transcripts. Hence, it is likely that the
most frequently observed transcript, which possesses both the
‘MATACK’ and ‘MKRAAAK’ exons, generates both the short and
long isoforms by alternative translation. Indeed, we observed
that if a Ube3a cDNA containing both exons is placed behind an
exogenous promoter, it efficiently generates both isoforms, and
only upon mutating the ATG of the mUBE3A-Iso3 ‘MKRAAAK’
exon does it uniquely generate the longer mUBE3A-Iso2 ‘MAT-
ACK’ containing protein (9). Surprisingly, the Kozak sequence
appears to be a bit less optimal for the ‘MKRAAAK’ exon com-
pared to the one for the ‘MATACK’ exon, hence it is unclear why
the ATG of ‘MKRAAAK’ is used so efficiently. Possibly, tertiary
structure of the mRNA affects the accessibility of the different
initiation codons, as well as the commitment of the ribosome to
an initiation codon, after the ribosome has recognized it (27,28).
In conclusion, our current data, together with previous obser-
vations in mice (9,12), show that the conserved subcellular dis-
tribution of human and murine UBE3A is mediated by non-
homologous isoforms. The finding that the two most abun-
dant human UBE3A isoforms are both nuclear emphasize an
important nuclear function of UBE3A in human, as was also
shown in mice (9). However, the observation that the mutation
that caused the hUBE3A-Iso3 to become nuclear occurred after
the appearance of the cytosolic hUBE3A-Iso2, could suggest an
evolutionary pressure to maintain a cytosolic pool of UBE3A.
Materials and Methods
Cell lines
Mouse hippocampal primary neurons used for localization stud-
ies were isolated from E16.5 male and female Ube3amE115X/p+
embryo brains [Ube3atm2Yelg (MGI: 5911277)] (29) in the FvB/N-
HanHsd background (designated as ‘AS’ mice). Cells were cul-
tured on poly-d-lysine coated glass coverslips at 37◦C in a 5%
CO2 humidified incubator in Neurobasal™ medium (NBM; Ther-
moscientific, 2 110 304) supplemented with 1% penicillin and
streptomycin, 1% Glutamax (Invitrogen) and 2% B27 (NBM+++).
For transfections, iPSCs derived from a Dutch AS patient
(UBE3A maternal nonsense mutation W577∗) were differentiated
to neurons as previously described (30) with slight modifications.
Namely, on day 15 cells were passaged 1:4 using collagenase
or ACCUTASE™ (Stemcell technologies, #07920), passage 1, and
further expanded in NPC medium. After passage 3, the NPC
culture was purified using fluorescence-activated cell sorting
(FACS), as described previously (31). NPCs were detached from
the culture plate and resuspended into a single cell solution.
CD184+/CD44−/CD271−/CD24+ cells were collected using a FAC-
Saria III (BD bioscience) and expanded.
In order to visualize endogenous UBE3A expression in iPSC
derived neurons, a commercial cell line (GM25256, Coriell Insti-
tute) was differentiated with the same protocol (30) and stained
on week 8 of differentiation.
U2OS cells (ATCC HTB-96) were cultured in DMEM GlutaMAX
(Thermo Scientific, 10569010) supplemented with 10% fetal calf
serum and 1% penicillin and streptomycin.
Plasmid construction
The original sequence for hUBE3A-Iso1 was obtained from
Addgene (Plasmid # 8657). This sequence was used for the
construction of hUBE3A-Iso2 and hUBE3A-Iso3, by addition of
the N-terminal extensions using PCR. Primers and plasmids used
in this study are listed in Supplementary Material, Tables S2
and S3, respectively. The exchange of the N-terminal extensions
between mUBE3A-Iso2 and hUBE3A-Iso3 was generated using
site-directed mutagenesis via PCR amplification and using as
template hUBE3A-Iso3 and mUBE3A-Iso2, respectively. UBE3A N-
terminal variation constructs were generated taking advantage
of the same approach and using as template hUBE3A-Iso3.
Amplified fragments were originally cloned into the TOPO
vector using a TOPO™ TA Cloning™ Kit (Life Technologies)
and sequence verified. For all neuronal transfections UBE3A
constructs were cloned into a dual promoter expression
vector, expressing the gene of interest under a CAG promoter
and tdTomato under a PGK promoter, ensuring independent
expression of the reporter gene (16). UBE3A isoforms were
cloned in the multiple cloning site of the vector downstream
of the CAG promoter and followed by a transcription terminator
sequence (Supplementary Material, Figure S1B). mUBE3A-Iso2
and mUBE3A-Iso3 constructs have been previously described
(9).
Transfections
On DIV7, mouse hippocampal primary neurons were transferred
in NBM supplemented with glutamine (500 μM), and their condi-
tioned medium was temporarily stored at 37◦C, 5% CO2. A total
of 1.8 μg of the desired construct was complexed with Lipofec-
tamine 2000 (Invitrogen, 11668-019) and added to the neurons.
After 1 h of incubation at 37◦C in 5% CO2, the medium was
replaced by the previously stored conditioned medium. Neurons
were fixed 3 days post-transfection.
iPSC-derived neural network cultures were transfected after
6 weeks of differentiation using lipofectamine 3000 (Ther-
moFisher, L3000001) according to manufacturer’s instructions.
Cells were fixed 2 days post-transfection.
U2OS cells were seeded 24 h prior to transfection in non-
coated coverslips in a 12-well plate (∼150.000 cells per well). On
the day of transfection, a total of 1.8 μg of the desired construct
was mixed with Polyethylemine (PEI) in a ratio of 3:1 (v/v) and
added to the cells. After a 6 h incubation the PEI containing
medium was removed and replaced by fresh medium. Cells were
fixed 2 days post-transfection.
Immunofluoresence
Primary hippocampal neurons were fixed by incubation with
0.5 mL of 4% paraformaldehyde (PFA)/4% sucrose at room







g/article/29/18/3032/5900569 by guest on 19 February 2021
Human Molecular Genetics, 2020, Vol. 29, No. 18 3041
temperature, a primary antibody mix, containing anti-UBE3A
(1:750, Sigma Aldrich, SAB1404508) and anti-MAP2 (1:500,
Synaptic Systems, 188 004), dissolved in GDB solution (0.1% (w/v)
gelatin, 0.3% (v/v) Triton X-100, 450 mM NaCl, 16 mM phosphate
buffer (pH 7.4)) was added to the coverslips, which were then
incubated overnight at 4◦C, in a dark and moist chamber.
Notably, the UBE3A antibody is a monoclonal antibody directed
against amino acid residues 318-417 of UBE3A (hUBE3A-Iso1).
This sequence is 100% conserved between all three isoforms.
The use of this antibody has previously been optimized and
validated in the lab for immunocytochemistry applications
(Fig. 1). The next day, following three washes with PBS at room
temperature, secondary antibody mix dissolved in GDB solution
was added to the coverslips, consisting of anti-mouse Alexa 488
(1:200, Jackson Immunoresearch, 715-545-150) and anti-guinea
pig Alexa 647 (1:200, Jackson Immunoresearch, 706-605-148),
for 1 h at room temperature, in a dark and moist chamber.
Subsequently, coverslips were washed three times with PBS, and
DAPI (ThermoFisher Scientific, D1306) was used to visualize the
nuclei. Ultimately the coverslips were washed three times with
PBS and mounted on glass slides, using Mowiol 4–88 (Sigma-
Aldrich, 81 381). The same procedure was followed when staining
U2OS cells, but without including MAP2 antibody staining.
Human neurons were fixed using 4% formaldehyde in PBS
and stained using immunocytochemistry. Primary antibody
incubation was done overnight at 4◦C, secondary antibody
incubation was done for 2 h at room temperature, both in a
staining buffer [0.05 M Tris, 0.9% NaCl, 0.25% gelatin, and 0.5%
Triton X-100 (Sigma, T8787) in PBS (pH 7.4)]. Primary antibodies
used were UBE3A (1:750) and MAP2 (1:500), secondary antibodies
conjugated to Alexa-488 and Alexa-647 were used at a dilution
of 1: 200. Nuclei were visualized using DAPI (ThermoFisher
Scientific, D1306). Samples were embedded in Mowiol 4-88
(Sigma-Aldrich, 81 381). All antibodies used in this study are
listed in the Reagents and Tools Table. All images were acquired
with a LSM700 confocal microscope (Zeiss).
Basic local alignment search tool (BLAST) analysis
In order to identify all reported protein isoforms of UBE3A across
evolution, a series of BLAST analyses were performed. Using the
NCBI platform of National Institute of Health (32), and cross-
referencing in the Ensembl platform (33), we performed a BLAST
analysis against protein sequences (BLASTP) using as query the
residues 1–16 of hUBE3A-Iso3 (Fig. 1A). The results of the BLASTP
were arranged in an order corresponding to the evolutionary
tree of mammals and ClustalOmega (34) and Jalview (35) were
used to visualize the multiple sequence alignment, the degree
of sequence conservation and the consensus sequence.
Using the DNA sequence of exon 4 of hUBE3A as query,
we performed BLAST analyses against DNA sequences at the
Ensembl platform with the search sensitivity set at ‘short
sequences.’ The output sequences were manually inspected
and all exon 4-like sequences were mapped on the genome of
the respective organisms to confirm that the sequences were
present in the UBE3A locus.
RNA-seq dataset and transcripts analysis
For the analysis of human UBE3A transcripts in brain cortex, we
utilized an RNA-seq dataset of cortical tissue specimens (17). The
raw sequencing data were imported to the Galaxy web platform
for mapping the reads to the genome (36). CutAdapt (Galaxy
Version 11.16.5) was used to trim reads of low quality (threshold
set at 20) and consecutively filter out reads with a read length
lower than 75 nucleotides. Read quality was assessed by FastQC
(Galaxy Version 0.72 + galaxy1). Using the STAR algorithm (37)
(Galaxy Version 2.7.2b), within the GALAXY platform, paired-end
reads were aligned to the human reference genome (GRCh38).
Transcript assembly was guided by the reference annotation file
Gencode v34 (38). The mapped dataset was viewed in the Inte-
grative Genomic Viewer IGV 2.3 (39) and an exon junction anal-
ysis was performed, extracting the respective Sashimi curves.
We counted, for each exon, the total number of junctions in
the whole dataset. Considering that exon 6 (Fig. 4A) should be
present in all protein-coding UBE3A transcripts, we calculated
the junctions of each upstream exon with exon 6. Of these, we
summed all exon junction counts that would encode for each
individual isoform and normalized this against the total number
of exon junctions between exon 6 and upstream exons, in order
to calculate the percentage in which each isoform is represented.
Considering all junctions between exons upstream of exon 6, we
list all possible combinations of alternative exon splicing that
are possible to occur according to the Sashimi analysis. Using
the same method, we quantified the relative amounts of UBE3A
isoforms in an RNA-seq dataset of human hES-derived NPCs,
after 6 weeks of differentiation, as previously described (19).
For the quantification of mUBE3A-Iso2 and mUBE3A-Iso3, an
RNA-seq dataset of four mouse hippocampi, of mice previously
described (40), was utilized. The samples were processed as
described above. CutAdapt (Galaxy Version 11.16.5) was used to
trim reads of low quality (threshold set at 20) and consecutively
filter out reads with a read length lower than 75 nucleotides.
Using the STAR algorithm (37) (Galaxy Version 2.7.2b), within the
GALAXY platform, paired-end reads were aligned to the mouse
reference genome (M24). Subsequently, the exon junctions and
transcript percentages were quantified in the same way as with
the human datasets.
Supplementary Material
Supplementary Material is available at HMG online.
Data Availability
All human RNA-seq datasets analyzed during this study are
included in the following published articles (and their supple-
mentary information files):
1. Human cortex RNA-seq data: DOI: 10.1038/s41598-017-
06145-8
2. Human embryonic cell derived neurons RNA-seq data: DOI:
10.1186/s13073-016-0347-3
The mouse RNA-seq data analyzed during this study have not
been deposited in a public repository, due to their inclusion in
an unpublished dataset, but are available from the lead contact
upon reasonable request.
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